Dave ...good news for you but probably not for AMRN Your cost is what Kaiser charges me My guess is that to retain market share or gain exclusivity AMRN has to drop their price to close or equal that of the generics . So if script numbers stay roughly where they are ...AMRN will be getting less on average per script.
The only silver lining here is that AMRN may be dumping their long term inventory at a low price ....better then writing it off . Welcome to AMRN generic V without them actually announcing a branded generic
News 
Market Data 
Discover 
AI
